Literature DB >> 11592788

1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue.

J K Aschenbrenner1, H W Sollinger, B N Becker, D A Hullett.   

Abstract

BACKGROUND: 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) plays an important role in regulating immune responses, in addition to its effects on bone metabolism. The cytokine transforming growth factor beta (TGF-beta) regulates diverse biological processes, including cellular proliferation and differentiation, immune modulation, and modulation of extracellular matrix deposition. 1,25-(OH)(2)D(3) interacts in vitro with Smad proteins, important regulators of TGF-beta signal transduction. We hypothesized that exogenous 1,25-(OH)(2)D(3) would alter levels of TGF-beta(1) and TGF-beta(1) signaling proteins in renal tissue.
METHODS: C57BL6 mice and Lewis rats were placed on diets with or without 1,25-(OH)(2)D(3) for 14 days. Renal lysates were examined for TGF-beta(1), vitamin D receptor (VDR), and Smad3 protein levels using a cell proliferation assay and Western blot analysis. Coimmunoprecipitation was used to determine if any interaction between VDR and Smad3 proteins occurs in vivo. Reverse transcription-polymerase chain reaction (RT-PCR) was used to assess messenger RNA (mRNA) levels for all of these molecules.
RESULTS: Vitamin D supplementation decreased VDR and Smad3 protein levels. Coimmunoprecipitation of VDR and Smad3 revealed a Smad3-VDR interaction in vivo. Vitamin D-treated rats had a significant (P = 0.001) reduction in bioactive renal TGF-beta(1). RT-PCR demonstrated no difference in mRNA expression for either VDR or TGF-beta(1).
CONCLUSION: Our results suggest that vitamin D has a significant effect in regulating levels of bioactive TGF-beta(1) and appears to affect aspects of the TGF-beta(1) signaling system. These effects, in combination with the immunomodulatory actions of vitamin D, may alter the evolution of chronic rejection in renal transplants. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592788     DOI: 10.1006/jsre.2001.6221

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  17 in total

1.  25-hydroxyvitamin D levels, race, and the progression of kidney disease.

Authors:  Michal L Melamed; Brad Astor; Erin D Michos; Thomas H Hostetter; Neil R Powe; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

2.  Serum fibroblast growth factor-23 is associated with incident kidney disease.

Authors:  Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

Review 3.  Role of vitamin D receptor activation in racial disparities in kidney disease outcomes.

Authors:  Utibe Essien; Narender Goel; Michal L Melamed
Journal:  Semin Nephrol       Date:  2013-09       Impact factor: 5.299

4.  Vitamin D levels are associated with epistaxis severity and bleeding duration in hereditary hemorrhagic telangiectasia.

Authors:  Lauren Marissa Weber; Jamie McDonald; Kevin Whitehead
Journal:  Biomark Med       Date:  2018-03-14       Impact factor: 2.851

5.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

6.  Vitamin D and kidney disease.

Authors:  Wisam Al-Badr; Kevin J Martin
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

7.  Chronic kidney disease, hypovitaminosis D, and mortality in the United States.

Authors:  Rajnish Mehrotra; Dulcie A Kermah; Isidro B Salusky; Myles S Wolf; Ravi I Thadhani; Yi-Wen Chiu; David Martins; Sharon G Adler; Keith C Norris
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

8.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

9.  1,25-dihydroxyvitamin D(3) regulates LPS-induced cytokine production and reduces mortality in rats.

Authors:  Xiao-Ping Qi; Pei Li; Gang Li; Zhen Sun; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

10.  VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome.

Authors:  Ursula Thiem; Georg Heinze; Rudolf Segel; Thomas Perkmann; Franz Kainberger; Ferdinand Mühlbacher; Walter Hörl; Kyra Borchhardt
Journal:  Trials       Date:  2009-05-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.